hrcak mascot   Srce   HID

Izvorni znanstveni članak
https://doi.org/10.2478/v10007-010-0022-y

Statistical analysis of low molecular mass heparin nanoencapsulation

VAISHNAVI GANTI ; Laboratory of Future Nanomedicines and Theoretical Chronopharmaceutics, University of Missouri-Kansas City, School of Pharmacy, Division of Pharmaceutical Sciences, Kansas City MO 64110
ABEBE ENDALE MENGESHA ; Laboratory of Future Nanomedicines and Theoretical Chronopharmaceutics, University of Missouri-Kansas City, School of Pharmacy, Division of Pharmaceutical Sciences, Kansas City MO 64110
JACOB MARSZALEK ; University of Missouri-Kansas City, School of Education, Division of Counseling & Education Psychology, Kansas City, MO 64110
BI-BOTTI C. YOUAN ; Laboratory of Future Nanomedicines and Theoretical Chronopharmaceutics, University of Missouri-Kansas City, School of Pharmacy, Division of Pharmaceutical Sciences, Kansas City MO 64110

Puni tekst: engleski, pdf (194 KB) str. 281-293 preuzimanja: 354* citiraj
APA 6th Edition
GANTI, V., ENDALE MENGESHA, A., MARSZALEK, J. i YOUAN, B.C. (2010). Statistical analysis of low molecular mass heparin nanoencapsulation. Acta Pharmaceutica, 60 (3), 281-293. https://doi.org/10.2478/v10007-010-0022-y
MLA 8th Edition
GANTI, VAISHNAVI, et al. "Statistical analysis of low molecular mass heparin nanoencapsulation." Acta Pharmaceutica, vol. 60, br. 3, 2010, str. 281-293. https://doi.org/10.2478/v10007-010-0022-y. Citirano 27.06.2019.
Chicago 17th Edition
GANTI, VAISHNAVI, ABEBE ENDALE MENGESHA, JACOB MARSZALEK i BI-BOTTI C. YOUAN. "Statistical analysis of low molecular mass heparin nanoencapsulation." Acta Pharmaceutica 60, br. 3 (2010): 281-293. https://doi.org/10.2478/v10007-010-0022-y
Harvard
GANTI, V., et al. (2010). 'Statistical analysis of low molecular mass heparin nanoencapsulation', Acta Pharmaceutica, 60(3), str. 281-293. doi: https://doi.org/10.2478/v10007-010-0022-y
Vancouver
GANTI V, ENDALE MENGESHA A, MARSZALEK J, YOUAN BC. Statistical analysis of low molecular mass heparin nanoencapsulation. Acta Pharm. [Internet]. 2010 [pristupljeno 27.06.2019.];60(3):281-293. doi: https://doi.org/10.2478/v10007-010-0022-y
IEEE
V. GANTI, A. ENDALE MENGESHA, J. MARSZALEK i B.C. YOUAN, "Statistical analysis of low molecular mass heparin nanoencapsulation", Acta Pharmaceutica, vol.60, br. 3, str. 281-293, 2010. [Online]. doi: https://doi.org/10.2478/v10007-010-0022-y

Sažetak
The objective of this study was to use Box-Behnken design (BBD) to investigate the influence of formulation variables on the properties of heparin-loaded poly(lactic-co-glycolic acid) (PLGA)-Eudragit-RLPO (E-RLPO) nanoparticles (NP) in terms of mean diameter (as size) and drug encapsulation efficiency. The NPs were prepared by the double emulsion solvent evaporation method. The independent variables were: X1  olymer mass ratio (PLGA:E-RLPO) in the oil phase, X2  concentration of polyvinyl alcohol (PVA) as emulsion stabilizer, and X3  volume of the external aqueous phase (W2). Particle size (analyzed by dynamic light scattering) and encapsulation efficiency (EE, estimated by spectrophotometry) were the investigated responses. The polynomial equation obtained from regression analysis of the reduced model (p = 0.0002, F = 25.7952 and R2 = 0.96) provided an excellent fit. The optimal size for the NP was found to be 134.2 ± 16.5 nm with formulation variables of 48.2:61.8, 0.321 (%, m/V) and 263 mL for X1, X2 and X3, respectively. Probably, due to electrostatic interaction between the negatively charged drug and the positively charged E-RLPO, the percent EE of heparin was between 74.4 ± 6.5 % (lowest value) and 92.1 ± 5.3 % (highest value). The data suggest that BBD is a useful tool in rational design of heparin-loaded NPs.

Ključne riječi
heparin; nanoparticle; encapsulation efficiency; Box-Behnken design

Hrčak ID: 53492

URI
https://hrcak.srce.hr/53492

[hrvatski]

Posjeta: 597 *